According to the American Diabetes Association's Standards of Care, GLP-1 RAs with proven cardiovascular benefit, such as semaglutide, may be considered as first-line therapy in patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or high cardiovascular risk, independent of metformin use
In SUSTAIN 6, the largest trial investigating semaglutide, with the longest duration reported to date in subjects with high cardiovascular risk, mean pulse rate increases of 2.1 and 2.4 bpm were reported with semaglutide 0.5 and 1.0 mg, respectively, versus no change with placebo
For even more advanced planning, the peptide formula guide covers the science behind peptide selection and protocol design
Improve cerebral edema Early surgical decompression is a significant factor in improving the prognosis of cerebral edema caused by an ischemic stroke